Impact of Anti-Tuberculosis Drug Induced Liver Injury in China
Author Information
Author(s): Shang Penghui, Xia Yinyin, Liu Feiying, Wang Xiaomeng, Yuan Yanli, Hu Daiyu, Tu Dehua, Chen Yixin, Deng Peiyuan, Cheng Shiming, Zhou Lin, Ma Yu, Zhu Lizhen, Gao Weiwei, Wang Hongyuan, Chen Dafang, Yang Li, He Pingping, Wu Shanshan, Tang Shaowen, Lv Xiaozhen, Shu Zheng, Zhang Yuan, Yang Zhirong, Chen Yan, Li Na, Sun Feng, Li Xiaoting, He Yingjian, Garner Paul, Zhan Siyan
Primary Institution: Peking University Health Science Centre
Hypothesis
What is the incidence and impact of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) on tuberculosis treatment in China?
Conclusion
ATLI significantly affects the outcomes of anti-TB treatment, with a cumulative incidence of 2.55% among patients receiving treatment.
Supporting Evidence
- 106 patients developed ATLI with a cumulative incidence of 2.55%.
- Nausea, vomiting, and anorexia were the most common symptoms.
- ATLI patients had a 9.25-fold increased risk of unsuccessful treatment outcomes.
Takeaway
Some people who take medicine for tuberculosis can get sick from it, which can make it harder for them to get better.
Methodology
A population-based prospective study monitored 4,304 TB patients receiving DOTS treatment to estimate the incidence of ATLI.
Potential Biases
Potential bias due to the exclusion of patients with prior hepatitis C infection and alcohol consumption history.
Limitations
The study had non-responders and dropouts, which may affect the generalizability of the results.
Participant Demographics
Median age of participants was 42 years, with 71.6% male.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 2.04%–3.06%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website